Evaluation of a Candidate Vaccine Against Uropathogenic Escherichia Coli in Women With a Clinical History of Recurrent Urinary Tract Infection.
Phase of Trial: Phase I
Latest Information Update: 01 May 2017
Price : $35 *
At a glance
- Drugs JNJ 63871860 (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions; First in man
- Sponsors GlycoVaxyn
- 10 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 01 Aug 2014 New trial record